2005 - 2006

2005

Milestone payment from Merck after decision is made to proceed with clinical trials.
Merck decides to discontinue clinical trials and returns to preclinical studies.
The Swedish Medical Products Agency approves the Company’s application to initiate clinical trials of KB2115 (eprotirome).
Clinical phase Ia studies of KB2115 (eprotirome) are completed as planned.
Significant progress is made in the project on receptors for thyroid hormones, TR STAD, which is aimed at developing important drugs for treating metabolic disorders such as elevated blood lipids.
The research partnership with Wyeth is extended by one year.
Rights issue raises a total of SEK 279 million before transaction costs.

2006

Clinical phase I studies of KB2115 (eprotirome) are completed as planned.
Milestone payment from Wyeth after the selection of a clinical development candidate in the LXR collaboration.
KB5359 is selected as a candidate drug in the TR STAD project.
Partnership with Wyeth is extended by another year.
Milestone payment from Wyeth after decision to initiate clinical trials.
Merck initiates clinical phase I studies of a new ER compound.
Karo Bio and Radius announce a licensing agreement for a new class of compounds, selective androgen receptor modulators (“SARMs”) for treating osteoporosis.
Karo Bio presents preclinical data pointing to significant antidepressant effects from ER-beta agonists.
Swedish and Finnish drug regulators approve the first clinical phase II study of KB2115 (eprotirome) for treating high blood lipids.